Sava Reports World-First 10-Day Clinical Evidence for Continuous Glucose Monitoring

Why It Matters

The validation shows minimally invasive microsensors can match conventional CGM performance over extended wear, potentially expanding adoption beyond the current 1% of diabetics using CGMs and lowering barriers to continuous health monitoring. This breakthrough paves the way for scalable, multi‑biomarker platforms that could shift healthcare toward proactive, real‑time disease management.

Key Takeaways

• 10‑day CGM evidence from 46 diabetic participants.
• Microsensor MARD within 0.8% of commercial CGM.
• Sensor length 10× shorter, less tissue disruption.
• Accuracy drift only ~1.5% over ten days.
• Platform aims multi‑analyte monitoring, commercial 2027.

Pulse Analysis

Diabetes remains a global health challenge, with nearly 590 million adults affected in 2024 and projections soaring to 853 million by 2050. Continuous glucose monitors (CGMs) have reshaped diabetes care, yet adoption lags at roughly 1% of patients, constrained by invasiveness, cost, and wear‑time limitations. Sava Technologies’ 10‑day microsensor study directly addresses these pain points, offering a less intrusive alternative that could accelerate CGM uptake and stimulate broader market growth.

The core of Sava’s advantage lies in its microsensor architecture, which replaces the traditional 5‑10 mm filament with a sensor an order of magnitude shorter. This design minimizes skin disruption while still accessing interstitial fluid, delivering accuracy comparable to established CGMs—evidenced by a MARD gap of only 0.8 percentage points and a modest 1.5 % drift over ten days. Such performance metrics not only satisfy clinical benchmarks but also simplify regulatory pathways, positioning Sava for a pivotal 2026 trial and eventual 2027 commercial launch.

Beyond glucose, Sava envisions a modular platform capable of real‑time monitoring of multiple biomarkers, turning a single‑use diabetes tool into a versatile health‑data engine. With $32 million raised and manufacturing scaling underway, the company is poised to capitalize on the $12 billion CGM market while opening new revenue streams in preventive health. If successful, this technology could catalyze a shift from reactive testing to continuous molecular insight, reshaping how chronic diseases are managed at scale.